Comparative Pharmacology
Head-to-head clinical analysis: ALFENTANIL versus BUTORPHANOL TARTRATE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALFENTANIL versus BUTORPHANOL TARTRATE PRESERVATIVE FREE.
ALFENTANIL vs BUTORPHANOL TARTRATE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Butorphanol is a mixed agonist-antagonist opioid analgesic acting at mu- and kappa-opioid receptors; it exerts its analgesic effects primarily via kappa-opioid receptor agonism and partial mu-opioid receptor agonism/antagonism.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Adults: 1-2 mg intramuscularly or intravenously every 3-4 hours as needed for pain; alternatively, 0.5-1 mg intravenously every 3-4 hours. For epidural administration: 1-2 mg at the lumbar level, may repeat once after 60 minutes if needed.
None Documented
None Documented
Clinical Note
moderateAlfentanil + Torasemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide."
Clinical Note
moderateAlfentanil + Etacrynic acid
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Etacrynic acid."
Clinical Note
moderateAlfentanil + Furosemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Furosemide."
Clinical Note
moderateAlfentanil + Bumetanide
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Terminal elimination half-life: 2.5-3.5 hours (IV); 4-6 hours (IM). In hepatic impairment, half-life may increase to 5-9 hours; in renal impairment, minimal change unless severe.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Primarily renal (70-80% as unchanged drug and metabolites; 5% unchanged), biliary/fecal (15-20%), with enterohepatic recirculation.
Category C
Category C
Opioid Analgesic
Opioid Analgesic
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Bumetanide."